Atara raises $150M in follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million on Feb. 28 through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an 18% discount to Atara's close of $42.55 on Feb. 27, when it proposed the offering after market hours.

Atara is conducting two Phase III trials of tabelecleucel (formerly ATA129) to treat Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (EBV-PTLD). Data from the first study are due in 1H19. The company also hopes to submit an MAA to EMA in 1H19 for the allogeneic therapy consisting of EBV-specific cytotoxic T lymphocytes...